The New England Journal of Medicine.

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

The New England Journal of Medicine.
May 1, 2025, 10:14 | Science
Gerry Hanna: Routine Scanning/surveillance for Cancer Metastases is not Beneficial and Maybe Harmful in Some Cases
Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, shared on X: "Routine Surveillance…
Apr 29, 2025, 09:47 | Science
Praveen Kumar Marimuthu: Neoadjuvant dostarlimab for Stage I–III dMMR solid tumors
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an…
Apr 28, 2025, 11:05 | Science
Yüksel Ürün: Organ preservation dream becoming reality
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared an article by Andrea…
Feb 9, 2025, 17:54 | Blog
David Steensma: Lentiviral vectors construct integration into TP53
David Steensma, Chief Medical Officer at Ajax Therapeutics, posted on X about recent paper by…
Jan 17, 2025, 09:03 | Science
Paolo Tarantino: Long term outcomes from KATHERINE are out
Paolo Tarantino, Clinical Research Fellow at the Dana-Farber Cancer Institute, shared a recent article by…
Jan 1, 2025, 09:33 | Blog
Top 10 GI cancer studies for 2024 suggested by Sharlene Gill
Sharlene Gill, Medical Oncologist and Medical Director, Staff Wellness and Engagement at BC Cancer, shared…
Dec 19, 2024, 21:31 | Science
Vincent Rajkumar: AQUILA is my 12th published randomized trial
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, posted on X…
Dec 15, 2024, 18:31 | Science
Dean Crowe: This is why we Rally On
Dean Crowe, Founder and CEO at the Rally Foundation for Childhood Cancer Research, shared on LinkedIn…
Dec 12, 2024, 13:36 | Blog
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Erika Hamilton, The Director of Breast Cancer Program at Sarah Cannon Research Institute, shared on…
Dec 10, 2024, 11:15 | Blog
Vincent Rajkumar: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, posted on X…
Dec 7, 2024, 19:26 | Blog
Estela Rodriguez: Fascinating report on utility of cfDNA for detecting occult cancers by Amy E. Turriff et al.
Estela Rodriguez, Associate Director of Community Outreach, posted on X about recent paper by Amy…
Sep 26, 2024, 14:27 | Blog
Mehdi Hamadani: Efficacy of axatilimab in chronic graft-versus-host disease
Mehdi Hamadani shared a post on X, about recent paper published in The New England…
Sep 21, 2024, 13:04 | Blog
Guru Sonpavde: Adjuvant pembrolizumab improved outcomes in MIBC
Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…
Sep 21, 2024, 08:28 | Blog
Julie Hallet: Cabozantinib vs placebo for NETs
Julie Hallet, Associate Scientist at Sunnybrook Health Sciences Centre and Assistant Professor of General Surgery…
Sep 19, 2024, 16:49 | Insight
Elad Sharon: Proud to be part of the team that brought together the AMBASSADOR trial
Elad Sharon, Medical Oncologist at Dana-Farber, shared his recent article on X: "Incidentally, this is…
Sep 19, 2024, 09:29 | Insight
Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine
Guilherme Nader Marta, Advanced Clinical Fellow - Dana-Farber Cancer Institute, shared a post on LinkedIn: "DESTINY-Breast06…
Sep 18, 2024, 00:08 | Insight
Paolo Tarantino: Testing T-DXd vs chemo for endocrine-refractory HR+ MBC
Paolo Tarantino shared a post on X: "Previously presented at ASCO24 by Giuseppe Curigliano, the impressive…
Aug 24, 2024, 18:10 | Insight
First response of a child with neuroblastoma and a BARD1 germline mutation to PARP inhibitors - NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn: "NEW FINDINGS: A recent case study reported…
Aug 6, 2024, 03:03 | Insight
Vivek Subbiah: Sotorasib led to clinical improvement in disabling vascular malformations
Vivek Subbiah shared a post on LinkedIn about a recent paper titled "Sotorasib for Vascular…
Jul 11, 2024, 09:55 | Insight
Piotr Wysocki: Tisotumab vedotin improves outcomes of patients with recurrent cervical cancer
Piotr Wysocki recently posted on LinkedIn: "Vergote I et al. published results of a phase III…
Jul 9, 2024, 10:50 | Insight
Joseph McCollom: ACP and SIC aim to align medical care with patient goals
Joseph McCollom, Medical Oncologist at Parkview Cancer Institute, shared on X: "Vicki Jackson, American Academy of…
Jun 25, 2024, 14:38 | Insight
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results       …
Jun 7, 2024, 10:36 | Insight
Vincent Rajkumar: I’m updating my 2024 Review on myeloma for American Journal of Hematology
Vincent Rajkumar shared a post on X: “I’m updating my 2024 Review on myeloma for American…
Jun 7, 2024, 08:23 | Blog
Myriam Chalabi: The results of the NICHE-2 study now published in NEJM
Myriam Chalabi, Medical Oncologist and Cancer Immunotherapy researcher at Antoni van Leeuwenhoek, shared a post…
May 1, 2024, 00:59 | Insight
Angela Mastronuzzi: Yet another impactful and giant step in clinical research
Angela Mastronuzzi shared on LinkedIn: "Also out with The NEW ENGLAND JOURNAL of MEDICINE of the NEJM Group:…
Apr 20, 2024, 06:03 | Insight
Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!
Toni Choueiri shared on X/Twitter: "The long-awaited OS results from KEYNOTE-564 are out at the New…
Mar 8, 2024, 19:12 | Drugs
Naveen Pemmaraju: Rusfertide for patients with phlebotomy-dependent Polycythemia Vera (PV)
Naveen Pemmaraju posted on LinkedIn: ''Honored to share our brand new paper recently published in…
Nov 23, 2023, 15:44 | Blog
Chandler Park: We FINALLY have an effective FDA approved practice changing treatment for OUR patients that have a rising PSA after radical prostatectomy and/or radiation treatment
Oct 27, 2023, 04:23 | Insight
The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population - CUHK Medicine
CUHK Medicine shared on LinkedIn: " More than doubled lung cancer patients’ progression-free survival Lung…
All: 29 Posts: 1 - 100
Special Coverage